STEAP1 and cancer: The complementarity-determining regions of Fab120.545 are identical to those present in STEAP1 antibodies used in clinical trials (Fig. S1), indicating that the structure of the STEAP1-Fab120.545 complex could also be useful in engineering antibodies and other molecules that target STEAP1 in cancer.